Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

SELLAS Life Sciences (SLS) Research & Development (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Research & Development for 9 consecutive years, with $4.4 million as the latest value for Q4 2024.

  • Quarterly Research & Development fell 12.95% to $4.4 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $19.1 million through Dec 2024, down 20.46% year-over-year, with the annual reading at $16.0 million for FY2025, 16.1% down from the prior year.
  • Research & Development for Q4 2024 was $4.4 million at SELLAS Life Sciences, up from $4.4 million in the prior quarter.
  • The five-year high for Research & Development was $7.2 million in Q1 2023, with the low at $1.9 million in Q1 2020.
  • Average Research & Development over 5 years is $4.4 million, with a median of $4.5 million recorded in 2021.
  • The sharpest move saw Research & Development soared 129.83% in 2021, then decreased 28.76% in 2024.
  • Over 5 years, Research & Development stood at $2.8 million in 2020, then increased by 22.45% to $3.4 million in 2021, then skyrocketed by 72.3% to $5.8 million in 2022, then decreased by 12.81% to $5.1 million in 2023, then dropped by 12.95% to $4.4 million in 2024.
  • According to Business Quant data, Research & Development over the past three periods came in at $4.4 million, $4.4 million, and $5.2 million for Q4 2024, Q3 2024, and Q2 2024 respectively.